Bank of New York Mellon’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-282,907
| Closed | -$5.7M | – | 4681 |
|
|
2021
Q3 | $5.7M | Sell |
282,907
-26,396
| -9% | -$729K | ﹤0.01% | 2421 |
|
|
2021
Q2 | $11.5M | Buy |
309,303
+44,329
| +17% | +$1.36M | ﹤0.01% | 2050 |
|
|
2021
Q1 | $6.78M | Sell |
264,974
-13,624
| -5% | -$348K | ﹤0.01% | 2299 |
|
|
2020
Q4 | $6.14M | Buy |
278,598
+2,057
| +0.7% | +$45.3K | ﹤0.01% | 2258 |
|
|
2020
Q3 | $4.97M | Sell |
276,541
-12,738
| -4% | -$264K | ﹤0.01% | 2220 |
|
|
2020
Q2 | $7.35M | Buy |
289,279
+38,893
| +16% | +$838K | ﹤0.01% | 2004 |
|
|
2020
Q1 | $4.6M | Sell |
250,386
-42,068
| -14% | -$818K | ﹤0.01% | 2112 |
|
|
2019
Q4 | $6.44M | Buy |
292,454
+81,638
| +39% | +$1.64M | ﹤0.01% | 2210 |
|
|
2019
Q3 | $3.03M | Sell |
210,816
-6,098
| -3% | -$87.2K | ﹤0.01% | 2525 |
|
|
2019
Q2 | $3.42M | Sell |
216,914
-2,016
| -0.9% | -$27.4K | ﹤0.01% | 2517 |
|
|
2019
Q1 | $3.21M | Buy |
218,930
+837
| +0.4% | +$9.62K | ﹤0.01% | 2544 |
|
|
2018
Q4 | $2.33M | Buy |
218,093
+32,652
| +18% | +$429K | ﹤0.01% | 2653 |
|
|
2018
Q3 | $2.83M | Buy |
185,441
+24,543
| +15% | +$357K | ﹤0.01% | 2671 |
|
|
2018
Q2 | $1.97M | Buy |
160,898
+119,466
| +288% | +$1.5M | ﹤0.01% | 2848 |
|
|
2018
Q1 | $397K | Buy |
41,432
+21,853
| +112% | +$236K | ﹤0.01% | 3683 |
|
|
2017
Q4 | $177K | Sell |
19,579
-8,985
| -31% | -$66.1K | ﹤0.01% | 3975 |
|
|
2017
Q3 | $164K | Hold |
28,564
| – | – | ﹤0.01% | 3916 |
|
|
2017
Q2 | $91K | Sell |
28,564
-555
| -2% | -$1.75K | ﹤0.01% | 4047 |
|
|
2017
Q1 | $99K | Buy |
29,119
+350
| +1% | +$986 | ﹤0.01% | 4034 |
|
|
2016
Q4 | $83K | Buy |
28,769
+12,111
| +73% | +$43K | ﹤0.01% | 4055 |
|
|
2016
Q3 | $98K | Sell |
16,658
-2,841
| -15% | -$9.96K | ﹤0.01% | 4048 |
|
|
2016
Q2 | $58K | Sell |
19,499
-35,030
| -64% | -$144K | ﹤0.01% | 4154 |
|
|
2016
Q1 | $292K | Sell |
54,529
-3,440
| -6% | -$21.7K | ﹤0.01% | 3653 |
|
|
2015
Q4 | $688K | Sell |
57,969
-10,862
| -16% | -$124K | ﹤0.01% | 3387 |
|
|
2015
Q3 | $566K | Buy |
68,831
+10,455
| +18% | +$121K | ﹤0.01% | 3532 |
|
|
2015
Q2 | $814K | Buy |
58,376
+29,758
| +104% | +$546K | ﹤0.01% | 3446 |
|
|
2015
Q1 | $688K | Buy |
28,618
+1,030
| +4% | +$23.2K | ﹤0.01% | 3479 |
|
|
2014
Q4 | $454K | Buy |
27,588
+3,868
| +16% | +$44.6K | ﹤0.01% | 3660 |
|
|
2014
Q3 | $302K | Sell |
23,720
-46
| -0.2% | -$694 | ﹤0.01% | 3781 |
|
|
2014
Q2 | $537K | Buy |
23,766
+15,410
| +184% | +$279K | ﹤0.01% | 3587 |
|
|
2014
Q1 | $236K | Buy |
+8,356
| New | +$310K | ﹤0.01% | 3805 |
|
Other funds holding DRNA
Bank of New York Mellon's DRNA Position: Q4 2021 in Review
Bank of New York Mellon sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 282,907 shares — an estimated $5.7M sold.
Bank of New York Mellon first reported a position in DRNA in Q1 2014 and held it in 31 quarters. The position peaked at $11.5M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Bank of New York Mellon reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Bank of New York Mellon sold 282,907 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5.7M.
- Bank of New York Mellon first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 31 quarters.
- Bank of New York Mellon's Dicerna Pharmaceuticals, Inc. position peaked at $11.5M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.